SCHEMBL4160510

SCHEMBL4160510

O=C1CC[N+](C(=O)OCc2ccccc2)(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
TDP1 Q9NUW8 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
MAPK1 P28482 2/20 0.46
KMT2A Q03164 2/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
DDB1 Q16531 1/20 0.43
CRBN Q96SW2 1/20 0.43
LMNA P02545 2/20 0.42
HCAR2 Q8TDS4 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP12 P39900 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11256962 0.76 ALDH1A1 (0.46) ALDH1A1TDP1L3MBTL1MAPK1KMT2A
SCHEMBL9391305 0.75 ALDH1A1 (0.45) ALDH1A1TDP1L3MBTL1MAPK1KMT2A
SCHEMBL11233359 0.75 ALDH1A1 (0.45) ALDH1A1TDP1L3MBTL1MAPK1KMT2A
Cyclohexanone SCHEMBL2854193 0.73 CYP3A4 (0.54) ALDH1A1TDP1L3MBTL1MAPK1KMT2A
SCHEMBL6558775 0.73 CYP3A4 (0.44) ALDH1A1TDP1L3MBTL1MAPK1KMT2A
SCHEMBL4167580 0.72 ALDH1A1 (0.49) ALDH1A1TDP1L3MBTL1MAPK1KMT2A
SCHEMBL9785319 0.72 ALDH1A1 (0.49) ALDH1A1TDP1L3MBTL1MAPK1KMT2A
SCHEMBL15987361 0.72 CYP2C19 (0.49) ALDH1A1TDP1L3MBTL1MAPK1KMT2A
SCHEMBL1128419 0.71 ALDH1A1 (0.47) ALDH1A1TDP1L3MBTL1MAPK1KMT2A
SCHEMBL61861 0.71 KMT2A (0.66) ALDH1A1L3MBTL1KMT2ACYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069287-A1 SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS PFIZER INC 2009-03-12 US disclosed
EP-1957448-A1 SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS Pfizer Products Inc. (US) 2008-08-20 EP disclosed
WO-2007060526-A1 SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS PFIZER PRODUCTS INC. (US) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069287-A1 SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS BACE2, BACE1, PMP22 ALDH1A1 1601/4885TDP1 586/4885L3MBTL1 4208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.